```html

Impaired Glucose Tolerance (IGT): A Complete Patient‑Friendly Guide

Overview

Impaired Glucose Tolerance (IGT) is a pre‑diabetic state in which blood‑sugar (glucose) levels are higher than normal after a meal but not high enough to meet the diagnostic criteria for diabetes mellitus. It reflects a defect in the body’s ability to handle a glucose load, usually due to early insulin resistance combined with an inadequate insulin response.

Who it affects: IGT occurs most often in adults over 45 years of age, but it can be seen in younger individuals who have obesity, a sedentary lifestyle, or a strong family history of type 2 diabetes. Certain ethnic groups—including South Asians, Hispanic/Latino, African‑American, and Native American populations—have higher prevalence rates.

Prevalence: According to the World Health Organization (WHO) and the International Diabetes Federation, about 5–7 % of adults worldwide have IGT. In the United States, the CDC estimates that roughly 35 % of adults have some form of pre‑diabetes, and of those, ~30 % meet the criteria for IGT based on oral glucose tolerance testing (OGTT) <sup>1</sup>.

Symptoms

Many people with IGT are asymptomatic, which is why screening is crucial. When symptoms do appear, they are usually subtle and often mistaken for general fatigue or mild “borderline” diabetes.

• Increased thirst (polydipsia) – a mild, persistent sense of dryness.
• Frequent urination (polyuria) – especially at night (nocturia).
• Unexplained fatigue – feeling tired despite adequate sleep.
• Blurred vision – temporary focusing problems after meals.
• Slow healing of minor cuts or bruises – early sign of impaired tissue repair.
• Recurrent infections – especially yeast infections or urinary tract infections.
• Occasional hunger (polyphagia) – feeling hungry soon after eating.

Because these signs are often mild, most individuals discover IGT during routine health checks (e.g., cholesterol screening, blood pressure checks, or when a doctor orders a fasting glucose test).

Causes and Risk Factors

Underlying Pathophysiology

IGT results from a combination of:

• Insulin resistance – cells in muscle, fat, and liver do not respond adequately to insulin.
• Beta‑cell dysfunction – pancreatic β‑cells fail to increase insulin secretion sufficiently after a glucose load.
• Altered incretin response – hormones that normally amplify insulin release after meals (GLP‑1, GIP) are blunted.

Major Risk Factors

• Age ≥ 45 years
• Overweight or obesity (BMI ≥ 25 kg/m²; ≥ 30 kg/m² for higher risk)
• Physical inactivity (<150 min of moderate activity per week)
• Family history of type 2 diabetes (first‑degree relative)
• History of gestational diabetes or delivery of a baby > 4 kg
• Polycystic ovary syndrome (PCOS)
• Certain ethnic backgrounds (South Asian, African‑American, Hispanic, Native American)
• Elevated triglycerides or low HDL cholesterol
• Hypertension (BP ≥ 130/85 mmHg)
• Use of medications that raise glucose (e.g., glucocorticoids, atypical antipsychotics)

Diagnosis

IGT is identified through laboratory testing that evaluates how the body handles a standardized glucose challenge. The most widely accepted tests are:

1. Oral Glucose Tolerance Test (OGTT)

• Patient fasts overnight (8–12 hours).
• Baseline (fasting) plasma glucose is measured.
• Patient drinks 75 g of anhydrous glucose dissolved in 250–300 mL water.
• Plasma glucose is measured again 2 hours later.

Interpretation (WHO/ADA criteria):

• Fasting glucose < 126 mg/dL (7.0 mmol/L) AND 2‑hour glucose 140–199 mg/dL (7.8–11.0 mmol/L) → **Impaired Glucose Tolerance**.
• Fasting glucose 100–125 mg/dL → **Impaired Fasting Glucose (IFG)** (a related pre‑diabetes state).

2. Fasting Plasma Glucose (FPG)

While FPG alone cannot diagnose IGT, values in the 100–125 mg/dL range flag pre‑diabetes and often trigger an OGTT.

3. Hemoglobin A1c (HbA1c)

An HbA1c of 5.7–6.4 % indicates pre‑diabetes, but it does not differentiate between IFG and IGT. The OGTT remains the gold standard for specifically diagnosing IGT.

4. Continuous Glucose Monitoring (CGM) – Emerging Tool

In selected high‑risk patients, CGM can reveal post‑prandial glucose excursions that meet IGT criteria, though it is not yet standard practice.

Treatment Options

Management of IGT focuses on preventing progression to type 2 diabetes and reducing cardiovascular risk.

1. Lifestyle Modification (First‑Line Therapy)

• Weight loss: 5–10 % reduction in body weight can lower 2‑hour glucose by 10–20 mg/dL. Study: The Diabetes Prevention Program (DPP) showed a 58 % risk reduction with 7 % weight loss <sup>2</sup>.
• Physical activity: ≥150 min/week of moderate‑intensity aerobic exercise (e.g., brisk walking) plus 2–3 sessions of resistance training.
• Nutrition: Emphasize a Mediterranean‑style diet – high in vegetables, fruits, whole grains, legumes, nuts, olive oil; moderate fish and poultry; low in red meat, refined carbs, sugary beverages.
• Behavioral counseling: Structured programs (group or digital) improve adherence.

2. Pharmacologic Interventions

Medication is considered when lifestyle changes are insufficient, when the patient has high cardiovascular risk, or when progression to diabetes is imminent.

• Metformin – 500 mg twice daily (often increased to 850 mg twice daily). The DPP found metformin reduced diabetes incidence by 31 % overall and 39 % in participants <60 years or with BMI ≥ 35 kg/m² <sup>2</sup>.
• Thiazolidinediones (e.g., pioglitazone) – improve insulin sensitivity but carry risks of weight gain, edema, and possible heart failure; used rarely.
• Alpha‑glucosidase inhibitors (e.g., acarbose) – blunt post‑prandial glucose spikes; modest efficacy.
• GLP‑1 receptor agonists – emerging evidence suggests they may delay diabetes onset in high‑risk patients, though they are not yet FDA‑approved for IGT.

3. Surgical Options

Bariatric surgery (gastric bypass or sleeve gastrectomy) yields >70 % remission of pre‑diabetes in patients with BMI ≥ 35 kg/m², but it is reserved for severe obesity and after multidisciplinary evaluation.

Living with Impaired Glucose Tolerance

Daily Management Tips

• Monitor portion sizes – Use the plate method: half non‑starchy veg, a quarter lean protein, a quarter whole grains or starchy veg.
• Choose low‑glycemic-index carbs – barley, lentils, quinoa, sweet potatoes.
• Stay hydrated – Aim for 8 cups of water daily; limit sugary drinks and excessive fruit juice.
• Regular physical activity – Break up long sitting periods; take 5‑minute walks every hour.
• Weight‑watching tools – Track weight weekly; aim for gradual loss of 0.5–1 kg per week.
• Sleep hygiene – 7–9 hours of quality sleep; poor sleep worsens insulin resistance.
• Stress management – Mindfulness, yoga, or breathing exercises can lower cortisol‑mediated glucose spikes.
• Regular follow‑up – Repeat OGTT or HbA1c every 1–2 years, or sooner if weight changes.

Tools & Resources

• Free mobile apps for food logging (MyFitnessPal, Calorie Counter by Lose It!).
• Community diabetes‑prevention programs offered by health departments.
• Online education from reputable sources: American Diabetes Association (ADA), CDC’s “Prediabetes” portal.

Prevention

Because IGT is a reversible condition, primary prevention focuses on the same lifestyle pillars used in treatment.

• Maintain a healthy weight – Prevent weight gain of >5 % after age 30.
• Physical activity – At least 30 minutes of brisk walking most days; incorporate resistance training twice weekly.
• Healthy diet – Limit added sugars to <10 % of daily calories; increase fiber to ≥25 g/day.
• Regular screening – Adults 45 + should be screened for pre‑diabetes every 3 years; earlier screening for those with risk factors.
• Avoid tobacco – Smoking exacerbates insulin resistance and cardiovascular risk.

Complications

If IGT progresses untreated, the patient faces the same long‑term complications associated with type 2 diabetes, often with a latency of 5–10 years.

• Cardiovascular disease – Atherosclerosis, myocardial infarction, stroke; pre‑diabetes already carries a ~20 % increased risk of coronary heart disease.
• Microvascular damage – Early retinopathy, nephropathy (microalbuminuria), and peripheral neuropathy.
• Metabolic syndrome – Cluster of hypertension, dyslipidemia, and central obesity.
• Pregnancy complications – Higher odds of gestational diabetes and macrosomic infants.
• Progression to type 2 diabetes – Annual conversion rate of 5–10 % without intervention.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2023. https://www.cdc.gov/diabetes/data/statistics-report.html
2. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393‑403. doi:10.1056/NEJMoa012512
3. Mayo Clinic. Pre-diabetes – Symptoms, Causes, Treatment. https://www.mayoclinic.org/diseases-conditions/prediabetes/symptoms-causes/syc-20355278
4. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. 2006. https://www.who.int/publications/i/item/definition-and-diagnosis-of-diabetes-mellitus-and-intermediate-hyperglycaemia
5. American Diabetes Association. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1‑S210.

```